{"entity":{"id":"ursula-matulonis","kind":"person","name":"Ursula A. Matulonis","aka":[],"tldr":"Ursula Matulonis led the MIRASOL trial that gave ovarian cancer its first ADC with a survival benefit.","summary":"Ursula A. Matulonis is Chief of the Division of Gynecologic Oncology at Dana-Farber Brigham Cancer Center. She is a gynaecologic oncologist known for leading the MIRASOL trial of mirvetuximab soravtansine, which gave ovarian cancer its first antibody-drug conjugate, as well as trials of PARP inhibitors and bevacizumab combinations. Her selected paper reports mirvetuximab soravtansine in folate receptor alpha-positive, platinum-resistant ovarian cancer. She continues to lead trials of PARP inhibitors such as olaparib and of ADCs in ovarian cancer.","asOf":"2026-09-08","links":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/ursula-a-matulonis"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Matulonis%20UA%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":["folr1","parp"],"drugs":["mirvetuximab-soravtansine","olaparib"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["mirasol"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Division of Gynecologic Oncology","institutionId":"dana-farber","specialisms":["Ovarian cancer","PARP inhibitors","Antibody-drug conjugates"],"profiles":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/ursula-a-matulonis"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Matulonis%20UA%5BAuthor%5D"}],"papers":[{"title":"Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2309169","doi":"10.1056/NEJMoa2309169"}]},"route":"/people/ursula-matulonis/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"target":[{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"institution":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"},{"id":"sgo","kind":"institution","name":"Society of Gynecologic Oncology","route":"/institutions/sgo/"}],"trial":[{"id":"mirasol","kind":"trial","name":"MIRASOL / GOG-3045","route":"/trials/mirasol/"},{"id":"soraya","kind":"trial","name":"SORAYA","route":"/trials/soraya/"}]}}